Abstract
Non-peptide antagonists of the peptide hormone oxytocin (OT) with nanomolar OT receptor affinities are described. These compounds incorporate novel amido- and amidoalkylcamphor variations to the lead structure L-366,509 (1) to achieve receptor affinity enhancements of 2-3 orders of magnitude over that compound. The new OT antagonist L-367,773 (35) is shown to be an orally bioavailable agent with good duration in vivo and to inhibit OT-stimulated uterine contractions effectively in several in vitro and in vivo models.
MeSH terms
-
Animals
-
Binding Sites / drug effects
-
Female
-
Oxytocin / antagonists & inhibitors
-
Piperazines / chemical synthesis*
-
Piperazines / chemistry
-
Piperazines / pharmacology
-
Piperidines / chemistry
-
Piperidines / pharmacology*
-
Rats
-
Receptors, Oxytocin / antagonists & inhibitors*
-
Receptors, Oxytocin / metabolism
-
Spiro Compounds / chemical synthesis*
-
Spiro Compounds / chemistry
-
Spiro Compounds / pharmacology*
-
Structure-Activity Relationship
Substances
-
Piperazines
-
Piperidines
-
Receptors, Oxytocin
-
Spiro Compounds
-
L 366509
-
Oxytocin